Prostate Cancer Early-Detection Diagnostic Test

We are a public company traded on the Tel Aviv stock exchange and focused on investments and distribution of state-of-the-art Medical Technologies.  

We have exclusive distribution rights to a new and unique prostate cancer early-detection diagnostic test.

The test uses a first-in-class liquid biopsy platform focusing on changes to the structure of proteins in circulating fluids – highly specific to cancer.

The test is on the market in the USA and was adopted in the Cleveland Clinic. The test is included in NCCN and European guidelines and received FDA Breakthrough Device Designation.  

Our diagnostic test has gone through extensive scientific research validation, and we believe it is the most versatile prostate cancer diagnostic test available. The test is also very complementary to MRI-based diagnostic pathways.  

Presently we are looking for distributors for this new and unique prostate cancer early-detection diagnostic test.

Potential Business Partners: 
Cancer diagnostics distributors, private urology clinics, key opinion leaders, private laboratories, major medical centers/hospitals.

Target Countries:
Poland, Italy, Romania, Hungary, Bulgaria.

Company Info:

Year of Establishment: 2014
No.   of Employees:      1-10